Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER2 | P43116 | 18/20 | 0.75 |
| ▸ | PTGER3 | P43115 | 10/20 | 0.75 |
| ▸ | PTGDR | Q13258 | 7/20 | 0.53 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.53 |
| ▸ | PTGER4 | P35408 | 5/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13693325 | 1.00 | PTGER2 (0.75) | PTGER2PTGER3PTGDRPTGER1PTGER4 | |
| SCHEMBL13780837 | 0.93 | PTGER2 (0.65) | PTGER2PTGER3PTGDRPTGER1PTGER4 | |
| SCHEMBL13377434 | 0.92 | PTGER2 (0.64) | PTGER2PTGER3PTGDRPTGER1PTGER4 | |
| SCHEMBL14314748 | 0.92 | PTGER2 (0.64) | PTGER2PTGER3PTGDRPTGER1PTGER4 | |
| SCHEMBL12568632 | 0.92 | PTGER2 (0.64) | PTGER2PTGER3PTGDRPTGER1PTGER4 | |
| SCHEMBL13747568 | 0.90 | PTGER2 (0.61) | PTGER2PTGER3PTGDRPTGER1PTGER4 | |
| SCHEMBL13780849 | 0.90 | PTGER2 (0.61) | PTGER2PTGER3PTGDRPTGER1PTGER4 | |
| SCHEMBL13747816 | 0.89 | PTGER2 (0.60) | PTGER2PTGER3PTGDRPTGER1PTGER4 | |
| SCHEMBL13781107 | 0.89 | PTGER2 (0.60) | PTGER2PTGER3PTGDRPTGER1PTGER4 | |
| SCHEMBL13780851 | 0.88 | PTGER2 (0.62) | PTGER2PTGER3PTGDRPTGER1PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8377984-B2 | Substituted gamma lactams as therapeutic agents | ALLERGAN, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-8377984-B2 | Substituted gamma lactams as therapeutic agents | ALLERGAN, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-20090192159-A1 | SUBSTITUTED GAMMA LACTAMS AS THERAPEUTIC AGENTS | ALLERGAN, INC. | 2009-07-30 | — | — | US | disclosed |
| US-20090192159-A1 | SUBSTITUTED GAMMA LACTAMS AS THERAPEUTIC AGENTS | ALLERGAN, INC. | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192159-A1 | SUBSTITUTED GAMMA LACTAMS AS THERAPEUTIC AGENTS | GLA, B3GAT3, TGM1 | PTGER2 2641/4885PTGER3 2632/4885PTGDR 1276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.